News Releases

January 2021

January 11, 2021 1/11/2021 Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50 percent by FY2030 at the 39th Annual JP Morgan Healthcare Conference

January 11, 2021 1/11/2021 Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021 1/5/2021 Takeda Completes Sale of Select Non-Core Assets to Cheplapharm

December 2020

December 21, 2020 12/21/2020 Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

December 18, 2020 12/18/2020 U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

December 15, 2020 12/15/2020 U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

December 9, 2020 12/9/2020 Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

December 8, 2020 12/8/2020 Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

December 7, 2020 12/7/2020 Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders